Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC) | MicrobiomeTrials← Back to trialsNCT06988150
Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
RecruitingOBSERVATIONAL
Trial Details
Start: 2025-04-14Est. Completion: 2026-04-14
Enrollment target: 100 participants Locations- Cedars-Sinai Medical Center, Los Angeles, California, United States
Other microbiome trials you might be interested in
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoidCarcinoid TumorPancreatic NETSolid TumorSomatostatin Receptor
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize …
Iowa City, United StatesEst. completion Feb 2027
Pancreatic Ductal Adenocarcinoma
This study is open to adults with advanced pancreatic cancer. The study tests a type of immunotherapy. It is a protein t…
Los Angeles, United StatesEst. completion Mar 8, 2027
Adenocarcinoma, Pancreatic Ductal
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and mo…
Los Angeles, United StatesEst. completion Jan 1, 2031